title: No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
authors.affiliation: Department of Geriatrics, Broca Hospital, Paris, France. anne-sophie.rigaud@brc.ap-hop-paris.fr
authors.forename: A S
authors.initials: AS
authors.lastname: Rigaud
authors.forename: G
authors.initials: G
authors.lastname: André
authors.forename: B
authors.initials: B
authors.lastname: Vellas
authors.forename: J
authors.initials: J
authors.lastname: Touchon
authors.forename: J J
authors.initials: JJ
authors.lastname: Pere
mesh_terms: D000203:Activities of Daily Living; D000279:Administration, Cutaneous; D000284:Administration, Oral; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy*; D002219:Carbamates / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000008:administration & dosage; D005260:Female; D005602:France; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D008593:Menopause / Q000187:drug effects; D009483:Neuropsychological Tests; D048448:Phenylcarbamates; D011374:Progesterone / Q000008:administration & dosage; D000068836:Rivastigmine; D016896:Treatment Outcome
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D011374:Progesterone; D004958:Estradiol; D000068836:Rivastigmine